Searchable abstracts of presentations at key conferences in endocrinology

ea0008ds2 | Lectures | SFE2004

New insights into the pathogenesis of diabetic kidney disease

Flyvbjerg A

At present, diabetic kidney disease affects about 15-25 % of all type 1 diabetic patients and 20-40 % of all patients with type 2 diabetes. The mechanisms underlying the development of diabetic kidney disease are extremely complex and not yet fully understood. Among many potential pathogenic mechanisms responsible for the progression in diabetic nephropathy, metabolic factors beyond blood glucose, e.g. advanced glycation end-products (AGEs), and growth factors/cytokines have b...

ea0002p33 | Diabetes and metabolism | SFE2001

NORMALISATION OF 150 kDa INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3 TERNARY COMPLEX FORMATION DURING PEGVISOMANT THERAPY IN ACROMEGALY

Parkinson C , Flyvbjerg A , Trainer P

Serum IGF-I is increasingly used, and IGFBP-3 has been proposed, as a marker of treatment efficacy in patients with acromegaly. IGF-I bioactivity and half-life are dependent on the degree of IGF-I incorporation into 150kDa ternary complexes with IGFBP-3 and ALS. When serum GH is lowered in patients with acromegaly all three ternary complex components decline, but effects on ternary complex formation have not been described. We investigated GH action on ternary complex formatio...

ea0026p569 | Cardiovascular endocrinology and lipid metabolism | ECE2011

α-Defensins are novel biomarkers of low grade inflammation with strong prognostic impact in patients with heart failure

Kistorp C , Christensen H M , Frystyk J , Flyvbjerg A , Hildebrandt P , Schou M , Faber J

Introduction: α-Defensins are recently described peptides, which are part of the innate immune system. Increased circulating levels are observed in conditions associated with chronic low grade inflammation, such as ischemic heart disease and in diabetes mellitus (DM). Recently we reported adverse prognostic implications of high α-defensins in patients with type 1 DM. However, it is not clear whether this finding may be generalized to include other groups such as pati...

ea0011p244 | Cytokines and growth factors | ECE2006

CD4 T-cell count improves during sustained IGF-I response following low dose growth hormone therapy in HIV-infected patients on stable antiretroviral regimens. A pilot study

Andersen O , Hansen BR , Flyvbjerg A , Madsbad S , Ørskov H , Nielsen JO , Iversen J , Haugaard SB

Objective: High dose growth hormone (rhGH) regimens (2 to 4 mg/day) have been shown to increase circulating insulin-like growth factor (IGF)-I to supra-physiological levels in human immunodeficiency virus (HIV)-infected patients on combined antiretroviral therapy (CART). This setting may improve immunologic output. However, a high plasma IGF-I concentration has detrimental effects on glucose metabolism, which hampers the use of high dose rhGH regimens.Me...

ea0011p388 | Diabetes, metabolism and cardiovascular | ECE2006

Plasma N-terminal pro-brain natriuretic peptide and adiponectin levels increases during weight loss

Kistorp C , Bliddal H , Flyvbjerg A , Frystyk J , Hildebrandt P , Faber J

Objective: The cardiac hormone brain natriuretic peptide (BNP), including the N-terminal fragment of the prohormone (NT-proBNP) have in cross-sectional studies been demonstrated to be inversely associated with BMI. Clearance of these peptides by adipocyt specific receptors have been suggested. We therefore investigated the impact of weight loss on plasma levels of NT-proBNP and adiponectin in obese individuals.Methods: A total of 20 obese women and 2 men...

ea0003p175 | Growth and Development | BES2002

Abnormal collagen morphology and decreased bone strength in growth hormone deficient rats

Lange M , Qvortrup K , Svendsen O , Flyvbjerg A , Nowak J , Olgaard K , Petersen M , Feldt-Rasmussen U

Patients with growth hormone deficiency (GHD) have increased risk of bone fractures. Despite a well-known decrease in bone mineral density (BMD) and content (BMC) in these patients, these changes in bone mineralization cannot explain the increase in fracture rate alone. The purpose of this study was to evaluate collagen morphology in cortical bone from GHD rats in order to provide a further explanation for the increased fracture rate seen in GHD patients.<p class="abstext...

ea0014p231 | (1) | ECE2007

Pioglitazone treatment significantly decreases 5-alpha reductase activity and improves metabolic risk factors in PCOS

Glintborg Dorte , Hermann Anne Pernille , Hagen Claus , Veldhuis Johannes , Schmedes Anne , Frystyk Jan , Flyvbjerg Allan , Andersen Marianne

Objective: To investigate the effect of pioglitazone on cortisol metabolism in PCOS.Design: Thirty insulin resistant PCOS patients were randomized to either 16 weeks of pioglitazone (30 mg/day) or placebo treatment. Before and after intervention, patients underwent 24 h 20 min.-integrated blood sampling for measurement of cortisol and 24 h excretion of cortisol, cortisone and steroid metabolites (cortisol, corticosteron, androgen, and 17-hydroxyprogester...